Skip to main content
HALO
NASDAQ Life Sciences

Halozyme Reports Strong Q1 2026 Financials, Initiates New $1 Billion Share Repurchase Program

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$68.4
Mkt Cap
$7.868B
52W Low
$47.5
52W High
$82.22
52W Position info
44% above low
Off High info
17% below high
Rel. Volume info
1.7× avg
Market data snapshot near publication time

HALO sits 44% above its 52-week low of $47.5.

Summary

Halozyme reported strong Q1 2026 financial results, including a 43% revenue increase and 31% diluted EPS growth, alongside authorizing a new $1 billion share repurchase program.


Key Events · Earnings and Guidance · HALO

  • Strong Q1 2026 Financial Performance

    Total revenues increased by 43% to $376.7 million, net income rose 27% to $150.0 million, and diluted EPS grew 31% to $1.22 compared to Q1 2025.

  • New $1 Billion Share Repurchase Program

    The Board authorized a new program to repurchase up to $1 billion of common stock by December 31, 2028, with at least $400 million expected in 2026. This follows the previous $750 million program, which had $157.7 million remaining.

  • Key Partner Collaborations and Regulatory Approvals

    Recent highlights include FDA approval for argenx's VYVGART Hytrulo, new global collaboration and license agreements with GSK and Oruka for ENHANZE and Hypercon technologies, and Janssen's FDA approval of TECVAYLI in combination with DARZALEX FASPRO.

  • Increased Cash Position

    Cash and cash equivalents significantly increased to $309.7 million as of March 31, 2026, up from $133.8 million at December 31, 2025.


Analysis · HALO · Life Sciences

Halozyme Therapeutics delivered robust first-quarter 2026 financial results, with significant increases in revenue, net income, and diluted EPS. The company also announced a new $1 billion share repurchase program, demonstrating a strong commitment to returning capital to shareholders. This positive financial and capital allocation news is further supported by multiple new and expanded collaborations and regulatory approvals for its ENHANZE and Hypercon technologies. However, the company noted a potential risk of a material interim impairment charge to intangibles and/or goodwill if a partner decides to return a Hypercon target by September 2026.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, HALO was trading at $68.40 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $7.9B. The 52-week trading range was $47.50 to $82.22. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

HALO - Latest Insights

HALO
Nov 19, 2026, 10:00 AM EST
Source: Seeking Alpha
Importance Score:
8
Price at Filing: $92.63
Real-time Price: $91.35 info
Change: -$1.28 (-1%) info
Market Cap: $10.415B info
HALO
Nov 06, 2026, 9:57 AM EST
Source: PR Newswire
Importance Score:
7
Price at Filing: $110.28
Real-time Price: $91.35 info
Change: -$18.93 (-17%) info
Market Cap: $10.415B info
HALO
Nov 05, 2026, 4:08 PM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $114.34
Real-time Price: $91.35 info
Change: -$22.99 (-20%) info
Market Cap: $10.415B info
HALO
Nov 05, 2026, 4:05 PM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $123.61
Real-time Price: $91.35 info
Change: -$32.26 (-26%) info
Market Cap: $10.415B info
HALO
Oct 07, 2026, 8:30 AM EDT
Source: PR Newswire
Importance Score:
9
Price at Filing: $110.00
Real-time Price: $91.35 info
Change: -$18.65 (-17%) info
Market Cap: $10.415B info